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Abstract
Group IIA secreted/synovial phospholipase A2 (GIIAPLA2) is an enzyme involved in the synthesis of eicosanoids such as
prostaglandin E2 (PGE2), the main eicosanoid contributing to pain and inflammation in rheumatic diseases. We designed, by
molecular modeling, 7 novel analogs of 3-{4-[5(indol-1-yl)pentoxy]benzyl}-4H-1,2,4-oxadiazol-5-one, denoted C1,a n
inhibitor of the GIIAPLA2 enzyme. We report the results of molecular dynamics studies of the complexes between these
derivatives and GIIAPLA2, along with their chemical synthesis and results from PLA2 inhibition tests. Modeling predicted
some derivatives to display greater GIIAPLA2 affinities than did C1, and such predictions were confirmed by in vitro PLA2
enzymatic tests. Compound C8, endowed with the most favorable energy balance, was shown experimentally to be the
strongest GIIAPLA2 inhibitor. Moreover, it displayed an anti-inflammatory activity on rabbit articular chondrocytes, as shown
by its capacity to inhibit IL-1b-stimulated PGE2 secretion in these cells. Interestingly, it did not modify the COX-1 to COX-2
ratio. C8 is therefore a potential candidate for anti-inflammatory therapy in joints.
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Introduction
Inflammation is a multi-faceted process involving numerous
enzymes, such as phospholipases A2 (PLA2s) and cyclo-oxygenases
(COXs) [1]. PLA2s catalyze the hydrolysis of cell-membrane
glycerophospholipids at the sn-2 position leading to the generation
of free fatty acids such as arachidonic acid. The later is
subsequently metabolized into potent pro-inflammatory mediators
such as eicosanoids (e.g. prostaglandin E2 [PGE2]) through a
pathway involving COX-1 and COX-2 in part [2]. PGE2 is the
main eicosanoid contributing to pain and inflammation in
rheumatic diseases [3,4]. Nonsteroidal anti-inflammatory drugs
(NSAIDs) reduce the production of PGE2, which leads to a
significant improvement in rheumatic symptoms. However, these
drugs exhibit gastrointestinal toxicity mainly because of a marked
decrease in COX-1 activity [4] and renal and blood pressure
toxicities mainly because of a decrease in COX-2 activity. COX-1
is constitutively expressed in most tissues and appears to be
responsible for maintaining normal physiological function. How-
ever, COX-2 is absent in most tissues under normal resting
conditions but is induced in inflamed tissues and is responsible for
increased PGE2 production. This activation has motivated the
development of selective COX-2 inhibitors. However, these
inhibitors also have severe side effects such as myocardial
infarction [5,6]. Overcoming this problem could involve the
development of novel anti-inflammatory agents to efficiently
inhibit the PLA2-dependent production of COX substrates
without impairing the balance between COX-1 and COX-2.
PLA2s represent a growing family of enzymes of two main
categories, intracellular and secreted. Among the 10 human
secreted PLA2s (sPLA2s) known to date, the most studied is the
non-pancreatic Group IIA, denoted GIIAPLA2, because of its
involvement in the pathogenesis of many inflammatory diseases
(for a review, see [7]). GIIAPLA2 was originally purified from the
synovial fluid of patients with rheumatoid arthritis [8,9,10]. The
number of rheumatoid arthritis-affected joints and the presence of
destructive erosion correlate with the amount of GIIAPLA2 in the
serum of patients [11]. Moreover, GIIAPLA2 induces an
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10914inflammatory response when injected in rabbit joints [12] and
exacerbates rat adjuvant arthitis after intradermal injection [13].
The systemic implication of sPLA2s in inflammation has
prompted a number of research groups to develop selective
inhibitors of different types of these enzymes. Some potent
candidates have been evaluated in phase II clinical trials.
Surprisingly, no effect was observed when such inhibitors were
used to treat patients with sepsis or rheumatoid arthritis [14,15].
This failure could be due to the complexity of the inflammation
process and the existence of compensatory pathways. However,
these molecules have been tested only in high-level systemic
inflammatory diseases, not in low-level inflammatory diseases such
as atherosclerosis, diabetes, Alzheimer’s, and osteoarthritis.
Varespladib, a sPLA2 inhibitor, was recently found to reduce
atherosclerosis in apolipoprotein-E-null mice [16]. Thus, the
efficacy of sPLA2 inhibitors in these low-level inflammatory
diseases should be re-examined.
We have developed various selective inhibitors of sPLA2s
[17,18,19,20,21]. Previously, we reported on the computer-
assisted design and synthesis of a series of novel oxadiazolone
derivatives that were shown to exhibit potent inhibitory properties
against GIIAPLA2 [20]. In this series, a Ca(II)-binding oxadiazo-
lone ring was connected through a polymethylene chain of varying
lengths to an indole ring, which has been shown to be involved in
apolar and cation-p interactions with GIIAPLA2 residues. The
optimal length of the linker was found to encompass 5 methylenes,
and the corresponding compound, (3-{4-[5-(indol-1-yl)pentoxy]-
benzyl}-4H-1,2,4-oxadiazol-5-one), is denoted C1 in the present
study. In the current work, the indole moiety was replaced by
other aromatic groups, which gave rise to compounds C2 to C8.
Using molecular modeling, we computed and ranked energy
balances for the binding of these inhibitors to GIIAPLA2. The
inhibitory potencies of C2 to C8 against GIIAPLA2 was analyzed
by enzymatic assay, and the anti-inflammatory activity of the most
potent compound, C8, was evaluated in IL-1b-treated articular
chondrocytes.
Results
Molecular modeling
We previously reported that one of the essential interactions
between C1 and the target GIIAPLA2 is Ca(II) bidentate chelation
by the oxadiazolone moiety in its anionic form [20]. Because C2-
C8 are structurally similar to C1 (Fig. 1), docking was performed
upon first anchoring the oxadiazolone ring in the same position as
compound C1, followed by energy minimization and molecular
dynamics. As was observed for compound C1, the lowest-energy
frames of C2-C8/enzyme complexes are stabilized by p–p and
cation-p interactions involving His6, Phe23, and Phe63 on the one
hand and Arg7 and Arg33 of GIIAPLA2 on the other. Table 1 lists
the energy values corresponding to the lowest-energy frames from
molecular dynamics.
Chemistry
As outlined in Figure 1, 4-(5-bromopent-1-yloxy)benzyl cyanide
1 is prepared according to Dehaen and Hassner [22] by mono-
substitution of 1,5-dibromopentane with 4-hydroxybenzyl cyanide
in moderate yield. Compound 1 is then condensed in 25% to 50%
yields, with 5-substituted indole derivatives or different aromatic
alcohols, through their sodium salts prepared prior to use, to give
2a–g. The nitrile function of 2a–g is converted into amidoxime,
by use of hydroxylamine released in situ from its HCl salt, to
provide 3a–g in 35% to 80% yields. The action of phenyl
chloroformate to the amidoximes 3a–g leads to the corresponding
Figure 1. Synthesis scheme. Reagents and conditions: (a) Br(CH2)5Br, K2CO3, DMF, RT, 10 days; (b) Ar-NH, K2CO3,C H 3CN, reflux; (c) NaOH, Abs
EtOH; (d) 1, DMF, RT, 24 h; (e) NH2OH-HCl, K2CO3, Abs EtOH; (f) PhOCOCl, Et3N, CH2Cl2; (g) toluene, reflux. The terms 1, 2a-g and 3a-g written in bold
refer to the C2-C8 precursors. The terms a to g written in bold in the bottom of the figure refer to the radicals (R) of the C2 to C8 compounds,
respectively. The radical of the C1 compound is also shown.
doi:10.1371/journal.pone.0010914.g001
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cyclizes intra-molecularly to generate the substituted oxadiazo-
lones C2-C8 in 34% to 50% yields.
In vitro inhibition of enzymatic activity of sPLA2s by C1-
C8
The compounds C1-C8 were submitted to fluorimetric assay to
determine their inhibitory potencies and selectivity towards human
GIIAPLA2 (hGIIAPLA2) versus porcine group IB PLA2 (pGIB-
PLA2) (Table 2). GIBPLA2 is an enzyme of the same family as
GIIAPLA2 (sPLA2) but is mainly involved in digestion of dietary
phospholipids and is secreted by the pancreas [23]. Lipophilicity
parameters, log P, of these products are calculated by use of
Rekker’s fragmental data [24] (Table 2). The molecules C1-C8
are specific inhibitors of hGIIAPLA2 because none inhibited
pGIBPLA2 at the highest concentration tested (100 mM). Such
selectivity implies that C1-C8 should not interfere with the
digestion process.
The experimentally measured IC50s for hGIIAPLA2 (Table 2)
are associated with the final energy balances, denoted dE2 in
Table 1. The ranking of C1-C8 in terms of IC50 is the same as
that of the dE2 magnitudes. In C2, the second phenyl ring is
substituted with the ether O in the ortho position and in C6 in the
para position. Both IC50 and dE2 values show C2 to have a
significantly enhanced affinity for PLA2 as compared with C6,
even though both are iso-lipophilic (Tables 1 and 2). In C2, the
biphenyl group has favorable van der Waals interactions with both
Phe23 and Val30 of the enzyme, but in C6, the interactions are
limited to Phe23. Such interactions could be further optimized, as
when the biphenyl ring was replaced by phenantrene in C8. The
lowest-energy complex is now stabilized by an enhanced overlap of
this ring with Phe63 (Fig. 2). However, the lipophilicity increases in
parallel, which could possibly limit the bioavailability of C8.W e
found C8 indeed endowed with the most favorable dE2 value
(Table 1), which was experimentally associated with the lowest
IC50 value (0.62 mM vs. 5 mM for C1).
At the other extreme, replacing the C1 indole ring by the
smaller and less electron-rich phenyl ring, as in C7, resulted in a
reduction of 10.3 kcal/mol in dE2 value. Thus, C7 can be
predicted to have the least inhibitory potency in the series. This
finding was confirmed by experimentation showing C7 to have the
highest IC50 value (35 mM vs. 5 mM for C1).
Similar to C1, compounds C3-C5 have a bicyclic ring, whereas
C3 possesses a benzo-1,3-thiazole instead of an indole ring. C4
and C5 have a chlorine and a methoxy substituent, respectively, in
position 5 of the indole. In C3-C5, the aromatic rings interact
simultaneously with His6, Arg7, and Val3, as was previously
observed for C1 [20]. The difference in activity between C4 and
C5 could be explained by additional electrostatic and/or van der
Waals interactions contributed by methoxy substitution. C3 has
anti-hGIIAPLA2 activity close to that of C1, along with
substantially reduced lipophilicity (2.88 vs. 3.81 for C1).
Thus, in the C1-C8 series, C8 has the most favorable dE2 value
and the lowest IC50 on human GIIAPLA2 activity, as evaluated by
enzymatic assay. On the bases of the IC50 values we focused our
cellular assays on the most potent compound C8, the sole
compound with a sub-micromolar activity. We thus chose to
evaluate the cytotoxicity and anti-inflammatory activity of C8 in
primary cultured rabbit articular chondrocytes treated with the
pro-inflammatory cytokine IL-1b, which is known to play a key
role in rheumatic diseases such as osteoarthritis (for reviews see
[25,26]). Chondrocyte is the unique cell type in joints, and the cell
model we chose is widely used to study the effect of inflammatory
stress on joint cells.
Evaluation of the cytotoxicity of C8 on articular
chondrocytes
We assessed the viability of the chondrocytes by MTT assay to
evaluate the cytotoxic effects of C8 on these cells. Chondrocytes
were treated for 20 h with 1 ng/mL IL-1b alone or 1 h after the
addition of C8 at 0.31 to 9.92 mM, which corresponded to 0.5- to
5-fold the IC50 of C8 on human GIIAPLA2 activity (Table 2).
Three different culture medium compositions were used: DMEM
alone, or supplemented with 0.1% BSA or 2% FCS. IL-1b had no
cytotoxic effects as compared with the untreated control condition
for the three culture media tested (Fig. 3). In chondrocytes cultured
in DMEM alone but with IL-1b, C8 had no cytotoxic effects at
Table 1. Energy balances (e=4) from performing single-point
Poisson-Boltzmann calculations of continuum solvation
energies.
Cpd Eint dEprot dElig dE1 Esolv Esolvlig Esolvprot dEsolv dE2
C1 2129.5 5.5 8.1 2115.9 2344.3 222.5 2385.1 63.3 252.6
C2 2131.8 7.8 10.6 2113.4 2343.6 223.9 2385.1 65.4 248.0
C3 2129.6 6.0 8.7 2114.9 2344.1 222.7 2385.1 63.7 251.2
C4 2130.1 5.6 8.0 2116.5 2343.7 221.7 2385.1 63.1 253.2
C5 2131.2 5.1 9.9 2116.2 2350.0 221.8 2385.1 56.9 259.3
C6 2130.8 10.0 9.5 2111.3 2350.1 221.7 2385.1 56.7 254.6
C7 2122.6 5.1 8.5 2109.0 2340.2 221.8 2385.1 66.7 242.3
C8 2135.1 7.1 9.8 2118.2 2349.7 221.8 2385.1 57.2 261.0
All energies are given in kcal/mol. Eint denotes the inhibitor (compounds C1 to
C8)-protein interaction energy, and dElig and dEprot the costs of conformational
energy rearrangements of the inhibitor and the protein, respectively, on
passing from their free to complexed states, and dE1 is the sum: Eint+ dElig +
dEprot. dE1 corresponds to a gas-phase complexation energy. Esolvprot and Esolvlig
denote the continuum solvation energies of the isolated protein and the ligand,
respectively, following gas-phase energy minimization in the absence of
complexation. They represent the energy cost necessary to dehydrate both
entities prior to complex formation. Esolvtot denotes the continuum solvation
energy of the complex. Thus, dEsolv =E solvtot –E solvlig –E solvprot, which
represents the resulting solvation energy balance. The overall energy balance
including solvation is denoted as dE2 = dE1 + dEsolv.
doi:10.1371/journal.pone.0010914.t001
Table 2. Inhibition of enzymatic activities of porcine
pancreatic group IB (pGIB) and human group IIA (hGIIA) PLA2s
by compounds C1 to C8 and their corresponding log P
values.
Cpd Log P* IC50 (mM)
hGIIAPLA2 pGIBPLA2
C1 3.81 5.060.7 .100
C2 5.59 10.061.5 .100
C3 2.88 5.061.2 .100
C4 4.57 6.561.8 .100
C5 3.91 2.560.5 .100
C6 5.59 3.060.2 .100
C7 3.64 3561.8 .100
C8 7.13 0.6260.15 .100
*: calculated using the Rekker’s hydrophobic fragmental constants
doi:10.1371/journal.pone.0010914.t002
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with 0.1% BSA or 2% FCS and IL-1b, C8 had no cytotoxic effects
at 0.31 to 9.92 mM (Fig. 3B and 3C). Thus, we evaluated the anti-
inflammatory activity of C8 in culture conditions from 0.31 to
1.24 mM in DMEM alone and from 0.31 to 4.96 mM in DMEM
supplemented with 0.1% BSA or 2% FCS.
Effect of C8 on IL-1b-stimulated PGE2 secretion in
articular chondrocytes
We tested the effect of C8 on the IL-1b-stimulated secretion of
PGE2 in chondrocytes. PGE2 synthesis takes placemainly in response
to cell activation by IL-1b, and its generation accounts for many of
the actions induced by this cytokine [27]. In vitro, IL-1b induces the
expression of COX-2 by chondrocytes, which results in increased
PGE2 production [28]. PGE2 release thus represents a powerful IL-
1b-a n dP L A 2-dependent inflammatory marker in our cell model.
Chondrocytes were treated for 20 h with IL-1b alone or 1 h after the
addition of C8.A se x p e c t e d ,I L - 1 b significantly stimulated PGE2
secretion by chondrocytes in the three different culture media: 23.3-,
18.3- and 2.8-fold induction as compared with untreated control
conditions, in DMEM alone or supplemented with 0.1% BSA or 2%
FCS, respectively (Fig. 4). In chondrocytes treated with IL-1b, C8
had a strong and statistically significant inhibitory effect on PGE2
secretion at all concentrations tested: from 0.31 to 1.24 mMi n
DMEM alone or from 0.31 to 4.96 mMi nD M E Ms u p p l e m e n t e d
with 0.1% BSA or 2% FCS (Fig. 4). In DMEM alone, at
concentrations of 0.31-, 0.62-, 0.94-, and 1.24-mM, C8 decreased
the production of PGE2 induced by IL-1bby 59-, 58-, 74-, and 80-%,
respectively (Fig. 4A). In DMEM supplemented with 0.1% BSA, at
concentrations of 0.31-, 0.62-, 0.94-, 1.24-, 2.48-, and 4.96-mM, C8
decreased the production of PGE2 induced by IL-1b by 31-, 30-, 45-,
43-, 81-, and 92-%, respectively (Fig. 4B). In DMEM supplemented
with 2% FCS, at concentrations of 0.31-, 0.62-, 0.94-, 1.24-, 2.48-,
and 4.96-mM, C8 decreased the production of PGE2 induced by IL-
1b by 26-, 48-, 49-, 54-, 68-, and 68-%, respectively (Fig. 4C). It is
important to note that C8 down-regulated the IL-1b-stimulated
secretion of PGE2 to the level of the control untreated condition at
4.96 mMi nD M E Ms u p p l e m e n t e dw i t h0 . 1 %B S Aa n da t2 . 4 8a n d
4.96 mM in DMEM supplemented with 2% FCS. The effect of C8
was then evaluated at the extreme concentrations (0.31- and 4.96-
mM) in DMEM supplemented with 2% FCS and containing
decreasing (1-, 0.5-, and 0.25-ng/mL) IL-1b concentrations
(Table 3). The anti-IL-1b inhibitory effect of C8 at 0.31 mM
increases when IL-1b concentration decreases. The inhibitory effect
of C8 at 4.96 mM does not change when IL-1b concentration
decreases. This is probably due to the fact that at 4.96 mM, the
inhibitory effect of C8 on IL-1b-induced PGE2 production is
maximal.A parallel cellular test was performed on the compound C1
whose IC50 is 5 mM (Table 2) and we observed that a 8 mMd o s eo f
C1, corresponding to 1.6-fold the IC50 of C1 on human GIIAPLA2
activity, does not decrease the stimulated PGE2 secretion by IL-1b at
1 ng/mL (data not shown). Thus, C8, but not C1, decreases the IL-
Figure 2. Representation of the most important interactions between C8 and the binding site of hGIIAPLA2 found from modeling.
The structure presented in the figure was derived from molecular dynamics using the Accelrys software and the cff91 force field (see Supporting
Information S1). In this presentation are shown in particular: a) the chelating of Ca(II) by the oxadiazolone moiety of C8, as well as Gly29 (G29), Gly31
(G31) and Asp48 (D48) of hGIIAPLA2 with their main-chain or side-chain carbonyls; b) the phenoxy binding site [(Leu2 (L2), Phe5 (F5), His6 (H6) and
Ala18 (A18)]; and c) the binding site of 5-(phenanthren-9-yloxy)pentyl [Asn1 (N1), Val3 (V3) and Phe63 (F63)].
doi:10.1371/journal.pone.0010914.g002
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three culture medium compositions used.
Effect of C8 on IL-1b-stimulated NO secretion in articular
chondrocytes
We tested the effect of C8 on the IL-1b-stimulated secretion of
NO in chondrocytes. NO is a mediator of immune and
inflammatory responses. In vitro, IL-1b induces the expression of
inducible NO synthase (iNOS) by chondrocytes, and consequently
an increase in NO production [29]. NO secretion, evaluated by
nitrite concentration in the cell culture medium, represents a
reliable IL-1b-dependent and PLA2-independent inflammatory
marker in our cell model. Chondrocytes were treated for 20 h with
IL-1b alone or 1 h after the addition of C8. As expected, IL-1b
Figure 3. Effect of IL-1b and C8 on viability of articular
chondrocytes. Chondrocytes were untreated (white bars) or treated
for 20 h with IL-1b alone (black bars) or 1 h after the addition of C8
(grey bars) in DMEM alone (A) or supplemented with 0.1% BSA (B) or 2%
FCS (C). Cell viability was evaluated by an MTT-based test. Data
represent the absorbance570nm - absorbance690nm and are expressed as
relative arbitrary units, where the IL-1b-untreated group represents
100%. Values are means 6 SEM (n=3 to 8 independent determina-
tions).
{ P,0.05,
{{ P,0.01,
{{{ P,0.001 between untreated and IL-1b-
treated groups; * P,0.05, ** P,0.01, *** P,0.001 between IL-1b- and
IL-1b+C8-treated groups.
doi:10.1371/journal.pone.0010914.g003
Figure 4. Effect of IL-1b and C8 on PGE2 secretion by articular
chondrocytes. Chondrocytes were untreated (white bars) or treated
for 20 h with IL-1b alone (black bars) or 1 h after the addition of C8
(grey bars) in DMEM alone (A) or with 0.1% BSA (B) or with 2% FCS (C).
PGE2 concentration was determined in conditioned culture medium,
and protein concentration was determined in whole-cell protein
extracts. Data represent the ratio of PGE2 concentration relative to
whole cell protein concentration (pg PGE2/mg proteins). Values are
means 6 SEM (n=3 to 7 independent determinations).
{ P,0.05,
{{ P,0.01,
{{{ P,0.001 between untreated and IL-1b-treated groups;
* P,0.05, ** P,0.01, *** P,0.001 between IL-1b- and IL-1b+C8-treated
groups.
doi:10.1371/journal.pone.0010914.g004
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three different culture media: 8.1-, 2.6-, and 2.0-fold induction as
compared with the control conditions, in DMEM medium alone
or supplemented with 0.1% BSA or 2% FCS, respectively (Fig. 5).
C8 did not significantly inhibit the IL-1b-stimulated nitrite
secretion in chondrocytes cultured in DMEM medium alone or
supplemented with 0.1% BSA (Fig. 5A, B). In DMEM
supplemented with 2% FCS, C8 did not inhibit the IL-1b-
stimulated nitrite secretion at 0.31-, 0.62-, and 0.94-mM and
slightly decreased by 17-, 19-, 21-% the IL-1b-induced nitrite
production at 1.24-, 2.48-, and 4.96-mM, respectively (Fig. 5C).
Thus, C8 did not inhibit the IL-1b-stimulated NO secretion in
DMEM alone or supplemented with 0.1% BSA and slightly
inhibited IL-1b-stimulated NO secretion in DMEM supplemented
with 2% FCS.
Effect of C8 on COX-1, COX-2, and iNOS protein levels in
articular chondrocytes
We evaluated the effect of C8 on COX-1, COX-2 and iNOS
protein levels in chondrocytes treated with IL-1b. Chondrocytes
were treated for 20 h with IL-1b alone or 1 h after the addition of
C8 (0.31-1.24 mM) in DMEM, and protein extracts were
examined by western blot analysis. As expected, COX-1 protein
was detectable but COX-2 and iNOS proteins were undetectable
in untreated control conditions (Fig. 6A). Moreover, IL-1b
treatment induced the expression of COX-2 and iNOS proteins
without affecting the level of COX-1 protein (Fig. 6A). In the
presence of IL-1b, C8 did not alter the COX-1, COX-2 and
iNOS protein levels (Fig. 6A). Consequently, the protein ratio of
COX-1 to COX-2 was not modified by C8 (Fig. 6B).
Discussion
Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit
COX-1 and COX-2, and selective COX-2 inhibitors are currently
used to reduce rheumatic symptoms. However, these drugs exhibit
gastrointestinal, renal, blood pressure and cardiovascular toxici-
ties. To overcome this problem, GIIAPLA2 inhibitors could be
developed to inhibit the production of COX substrates without
impairing the balance between COX-1 and COX-2. We designed
and synthesized 7 new oxadiazolone derivatives (C2 to C8)
derived from C1. Using molecular modeling, we computed and
ranked energy balances for the binding of these inhibitors to
GIIAPLA2. The energy balances (Table 1) taking into account
solvation effects show a correlation between dE2, the overall
energy balance for binding, and the experimentally measured IC50
for our novel compounds C1-C8. This finding should lend
additional credence to our previous results [20], despite the
approximations of the computational approach used in that study,
Table 3. Effect of C8 on PGE2 secretion by articular
chondrocytes incubated with different IL-1b concentrations.
C8 inhibitory effect (%inhibition)
IL-1b (ng/mL) C8 at 0.31 mM C8 at 4.96 mM
1 25* 68***
0.5 60* 67*
0.25 67 65
Chondrocytes were untreated or treated for 20 h with IL-1b (1-, 0.5-, or 0.25-ng/
mL) alone or 1 h after the addition of C8 (0.31- or 4.96-mM) in DMEM with 2%
FCS. PGE2 concentration was determined in conditioned culture medium, and
protein concentration was determined in whole-cell protein extracts. The PGE2
concentration was normalized relatively to whole cell protein concentration (pg
PGE2/mg proteins). The means of PGE2 concentrations from 3 independent
determinations were calculated and the anti-IL-1b inhibitory effect of C8 was
determined with the formula %inhibition =10021006[(mean PGE2 in IL-1b+C8
condition)/(mean PGE2 in IL-1b condition)]).
*P,0.05,
***P,0.001 between IL-1b- and IL-1b+C8-treated groups.
doi:10.1371/journal.pone.0010914.t003
Figure 5. Effect of IL-1b and C8 on nitrite secretion by articular
chondrocytes. Chondrocytes were untreated (white bars) or treated
for 20 h with IL-1b alone (black bars) or 1 h after the addition of C8
(grey bars) in DMEM alone (A) or supplemented with 0.1% BSA (B) or 2%
FCS (C). NO secretion was indirectly evaluated by determination of
nitrite concentration in conditioned culture medium. Protein concen-
tration was determined in whole-cell protein extracts. Data represent
the ratio of nitrite concentrations relative to whole-cell protein
concentration (pmol nitrites/mg protein). Values are means 6 SEM
(n=4 to 7 independent determinations).
{ P,0.05,
{{ P,0.01,
{{{ P,0.001 between untreated and IL-1b-treated groups; * P,0.05,
** P,0.01, *** P,0.001 between IL-1b- and IL-1b+C8-treated groups.
doi:10.1371/journal.pone.0010914.g005
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Boltzmann solvation energies for the most stable minima of the
molecular dynamics procedure. Our useful predictions made with
the present simplified energy potential may be due to the very local
changes we made in the C1-C8 series. These bear on the series’
sole terminal aromatic group and target a limited number of
amino acids, so that the accuracy of the energy potential may be
sufficient. We plan to study such energy balances with the
polarizable molecular mechanics procedure SIBFA [30], which,
along with the Langlet-Claverie methodology for Continuum
solvation [31], was recently used to investigate the binding of
inhibitors to metalloenzymes [32]. This study should also allow for
considering changes on other parts of the drugs as well.
One possible unfavorable feature of C8 is its enhanced
lipophilicity as compared with the other compounds. Nevertheless,
this feature did not prevent the pharmacological efficiency of C8
in chondrocytes. Reduction in Log P could be anticipated by
replacing phenantrene with heterocyclic analogs and/or substitu-
tion with hydrophilic groups. Such reductions were seen on
passing from compound C1 with an indole ring to C3 with a
benzothiazole. Nevertheless, the high lipophilicity of C8 should be
an interesting option for its prospective clinical development,
considering the possibility of local administration (intra-articular
infiltration).
The toxicity and anti-inflammatory activity of C8 were
evaluated in rabbit articular chondrocytes in primary culture.
The toxicity of C8 was assessed by MTT, which allows an
evaluation of the cell number and/or metabolic activity in cells.
C8 (from 0.31 to 9.92 mM) did not decrease cell viability in culture
medium supplemented with 0.1% BSA or 2% FCS but did (at 4.96
and 9.92 mM) in culture medium alone. This observation is
probably due to the cells being weakened in the absence of BSA or
FCS. We also observed, as expected, an increase in cell number
and/or metabolic activity in response to IL-1b. This effect
increases in the presence of C8, at non toxic doses, whatever the
culture conditions. Thus, depending on the culture conditions or
C8 doses, C8 increases or decreases cell number and/or metabolic
activity. Moreover, C8 from 0.31 mM inhibited IL-1b-induced
secretion of PGE2 by chondrocytes, corresponding to half of the
IC50 on human GIIAPLA2 activity evaluated in vitro by enzymatic
assay. Therefore, C8 could be a potent anti-inflammatory drug in
vivo. However, C8 did not inhibit IL-1b-induced NO secretion by
chondrocytes cultured in DMEM alone or supplemented with
0.1% BSA and slightly inhibited IL-1b-stimulated NO secretion in
DMEM supplemented with 2% FCS. These data suggest that the
anti-inflammatory property of C8 in chondrocytes mainly depends
on its capacity to inhibit PLA2 activity.
COX-1 is involved in normal physiological functions, whereas
COX-2 is involved in the inflammatory response. Anti-
inflammatory drugs such as NSAIDs and selective COX-2
inhibitors, used to treat rheumatic disease, have severe side
effects owing to impairment in the balance between COX-1 and
COX-2 [4,5,6]. Interestingly, the present work shows that the
potent PLA2 inhibitor C8 decreases PGE2 production without
impairing this balance. Consequently, C8 could be a useful
candidate in developing new anti-inflammatory drugs lacking
the side effects observed with NSAIDs and selective COX-2
inhibitors.
In summary, we report on the design, synthesis and testing of 7
C1 analogs that differ from C1 by indole substitution or by indole
replacement by other aromatic rings, the largest being phenan-
threne. Compounds C2-C8 show both inhibitory activity on
secreted/synovial GIIAPLA2 and selectivity as compared with
GIBPLA2, a pancreatic enzyme involved in the digestion of dietary
phospholipids. The order of interaction energies predicted by
molecular modeling of these compounds is associated with their
experimental IC50 values with GIIAPLA2 used as a target. The
most promising compound is C8 in terms of computed energy
balance for binding GIIAPLA2 and experimental potency towards
GIIAPLA2, namely one order of magnitude larger than that of
C1. In addition, C8 is endowed with anti-inflammatory activity in
articular chondrocytes by inhibiting IL-1b-stimulated PGE2
secretion in these cells. Furthermore, it does not modify the ratio
between the COX-1 and COX-2 isoenzymes. C8 is therefore an
attractive candidate for anti-inflammatory therapy in joints.
Experiments in animal models of rheumatic diseases are in
progress in our laboratory.
Materials and Methods
Ethics Statements
Experimental protocols using rabbits complied with French
legislation on animal experimentation and were approved by
Figure 6. Effect of IL-1b and C8 on the COX-1, COX-2, and iNOS
protein levels in articular chondrocytes. (A) Chondrocytes were
untreated or treated for 20 h with IL-1b alone or 1 h after the addition
of C8 in DMEM. 20 mg aliquots of whole-cell protein extracts were
examined by western blot analysis with antibodies against COX-1, COX-
2, and iNOS. a-tubulin immunodetection is shown as a control for
protein loading and transfer. Results from one representative experi-
ment in five are shown. (B) Intensities of the COX-1 and COX-2
immunoreactive bands evaluated by semi-quantitative scanning
densitometry. Data represent the COX-1/COX-2 protein ratio and are
expressed as relative arbitrary units, where the IL-1b-treated group
represents 1. Values are means 6 SEM (n=5 independent determina-
tions). No significant differences were found between the groups.
doi:10.1371/journal.pone.0010914.g006
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Me ´dicale)’s Committee for Animal Studies.
Molecular modeling
Molecular modeling is described in Supporting Information S1.
Synthesis of oxadiazolone derivatives
Synthesis of compounds C1-C8 is described in Supporting
Information S1.
In vitro PLA2 assay
Fatty-acid free BSA and pancreatic PLA2 were from Sigma.
hGIIAPLA2 was prepared as previously described [33]. The
fluorescent substrate for PLA2 assay, 1-hexadecanoyl-2-(10-
pyrenedecanoyl)-sn-glycero-3-phosphoglycerol, ammonium salt
(b-py-C10-PG) was from Molecular Probes (Eugene). PLA2
activity was evaluated as previously described [34] with b-py-
C10-PG used as a substrate (2 mM final concentration). In a
total volume of 1 mL, the standard reaction medium contained
50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 1 mM EGTA,
2 mM b-py-C10-PG, 0.1% fatty-acid free BSA and 6 ng/mL
pancreatic PLA2 or 1 ng/mL hGIIAPLA2.T h ef l u o r e s c e n c e
(lex =342nm and lem =398 nm) of the enzymatic reaction
medium was recorded for 3 min with use of a spectrofluorimeter
LS 50 (Perkin-Elmer) equipped with a Xenon lamp. The
reaction was initiated by the addition of CaCl2 (10 mM, final
concentration). The increase in fluorescence was continuously
recorded for 1 min, and PLA2 activity was calculated as
previously described [34]. When used, the inhibitor was added
to the reaction medium after introduction of BSA. The activity
is expressed in micromoles of fluorescent b-py-C10-PG hydro-
lyzed per min. The standard error of the mean of three
independent experiments was less than 10%, which allows for
the determination of the IC50 values (concentration of inhibitors
producing 50% inhibition) of each compound.
Isolation and culture of chondrocytes from rabbit
articular cartilage
Articular chondrocytes were isolated from 5-week-old Fauve de
Bourgogne female rabbits (CPA, Orleans, France) and cultured at
the first passage in conditions avoiding cell dedifferentiation as
previously described [35]. Cells were cultured at 37uC in 12-well
plates in Ham’s F-12 medium containing 10% FCS, 20 IU/mL
penicillin, and 20 mg/mL streptomycin (all from Invitrogen) until
nearly confluent. Then medium was replaced with DMEM
(Invitrogen) containing 20 IU/mL penicillin, and 20 mg/mL
streptomycin and, if necessary, 0.1% fatty acid free BSA (Sigma)
or 2% FCS. At this time the C8 compound dissolved in DMSO
(Sigma) was added to the medium (the amount of DMSO was kept
at 1% (v/v) in all the wells). 1 h after the addition of C8, IL-1b
(PeproTech) was added to the medium. Consequently, chondro-
cytes were incubated for 20 h with IL-1b and for 21 h with C8.
Evaluation of cell viability
At 18 h after the addition of IL-1b, 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide (MTT; Sigma) was added to
the cell culture medium at 0.5 mg/mL. Cells were incubated 2
more hours at 37uC. The medium was then removed, and DMSO
was added to dissolve the formazan crystals. The absorbance of
the resulting solution was spectrophotometrically measured at 570
and 690 nm (background). The value corresponding to absorban-
ce570nm - absorbance690nm was directly proportional to the number
and activity of the viable cells.
Determination of PGE2 and nitrite concentrations in
culture medium
20 h after the addition of IL-1b to the chondrocytes, culture
media were collected, and aliquots were stored at 280uC until
PGE2 and nitrite quantification. PGE2 concentration in culture
media was determined by use of an enzyme immunoassay (EIA) kit
(PGE2 EIA Kit-monoclonal; Cayman Chemical). Nitrite concen-
tration was determined by a spectrophotometry method based on
the Griess reaction [36]. Briefly, 200 mL of culture medium or
sodium nitrite (NaNO2, Merck) standard dilutions were mixed
with 100 mL Griess reagent [0.5% (w/v) sulphanilic acid (Merck),
0.05% (w/v) N(1-naphtyl)ethylenediamine (Merck), 30% (v/v)
acetic acid, 1.5 N HCl] and incubated for 10 min at 50uC. The
absorbance was measured at 540 nm.
Preparation of whole-cell protein extracts, protein
quantification and western blot analysis
Proteins were extracted from the cultured cells by addition of
lysis buffer [10 mM Tris (pH 7.4), 0.5% (v/v) NP40, 150 mM
NaCl, 1 mM PMSF, 0.1 mM Na3VO3, complete-EDTA-free
protease inhibitor cocktail (Roche)]. Cell lysates were centrifuged
for 15 min at 14000 rpm at 4uC and supernatants were collected.
Protein concentrations were determined by the Bradford method
[37] by use of the Protein Assay dye reagent (Bio-Rad). Protein
extracts (20 mg) were size-separated by SDS-PAGE in a 10% (w/v)
polyacrylamide gel and electroblotted to a nitrocellulose mem-
brane. Equal protein loading and transfer was confirmed by
staining the membrane with Ponceau Red [0.2% (w/v) in
H2O:acetic acid 99:1]. The membrane was sequentially incubated
with antibodies against COX-1 (1:200, Santa Cruz Biotechnolo-
gy), COX-2 (1:500, Santa Cruz Biotechnology), iNOS (1:400, BD
Biosciences) or a-tubulin (1:100, Santa Cruz Biotechnology) and
then with peroxidase-conjugated donkey anti-goat IgG (1:20000)
or donkey anti-rabbit IgG (1:200, both Santa Cruz Biotechnology).
Immunocomplexes were detected by an enhanced chemilumines-
cence kit (Amersham Bioscience). The membrane was stripped by
incubation in 0.2 M NaOH between successive immunodetec-
tions. Semi-quantitative scanning densitometry involved use of the
ImageJ program (NIH, USA).
Statistical analysis
Results are expressed as means 6 SEM for the number of
experiments indicated. Statistical analysis involved use of the
Kruskal-Wallis test, then the ANOVA Fisher’s test. A P,0.05 was
considered statistically significant.
Supporting Information
Supporting Information S1 Materials and Methods in chem-
istry and molecular modeling.
Found at: doi:10.1371/journal.pone.0010914.s001 (0.12 MB
DOC)
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